Xeris Biopharma Holdings (NASDAQ:XERS) announced their fourth-quarter financial results on March 6, 2024. The company reported a GAAP EPS of $(0.10), which matched analyst predictions.
Their quarterly sales reached $44.39 million, exceeding the analyst consensus estimate by 1.93%. This represents a significant 33.93% growth compared to the same period in the previous year.
Furthermore, Xeris Biopharma achieved total revenue of over $44 million in the fourth quarter of 2023, showing a remarkable 34% increase from the same period in the previous year.
XERS Stock Performance Analysis and Price Movement on March 6, 2024
XERS stock had a mixed performance on March 6, 2024, as it started the day with a slight increase but then dropped in pre-market trading. The stock is currently trading in the middle of its 52-week range, indicating that it is neither overbought nor oversold. Additionally, XERS is trading above its 200-day simple moving average, which is a positive sign for the stock’s long-term trend.
On March 6, XERS shares increased by $0.04, representing a 1.32% rise from the previous day’s closing price of $3.08. This increase may have been driven by positive news or market sentiment surrounding the company. However, the stock experienced a drop of $0.14 in pre-market trading, which may have been influenced by external factors such as market volatility or news developments.
Investors should carefully monitor XERS stock throughout the day to see how it performs in regular trading hours. The pre-market drop could potentially indicate a trend reversal or a temporary setback for the stock. It is important for investors to conduct thorough research and analysis before making any investment decisions based on short-term price movements.
XERS Stock Performance Review: Revenue Surges Despite Net Losses
XERS stock had an interesting performance on March 6, 2024, as the company reported its financial results for the past year and the third quarter. According to data from CNN Money, XERS reported a total revenue of $110.25 million for the past year, which was a significant increase of 122.32% compared to the previous year. In the third quarter alone, the company generated $48.32 million in total revenue, representing a 27.13% increase from the previous quarter.
Despite the positive revenue growth, XERS also reported a net loss for both the past year and the third quarter. The company’s net income was -$94.66 million for the past year, which was an improvement of 22.87% compared to the previous year. In the third quarter, XERS reported a net loss of -$12.19 million, showing a 38.57% increase from the previous quarter.
On a per-share basis, XERS reported earnings per share (EPS) of -$0.70 for the past year, which was an improvement of 55.06% compared to the previous year. In the third quarter, the company reported an EPS of -$0.09, representing a 38.89% increase from the previous quarter.
Investors will be closely monitoring the company’s future financial results and strategic initiatives to assess its long-term growth potential.
